David F. Stern

16.8k total citations · 3 hit papers
140 papers, 12.6k citations indexed

About

David F. Stern is a scholar working on Molecular Biology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, David F. Stern has authored 140 papers receiving a total of 12.6k indexed citations (citations by other indexed papers that have themselves been cited), including 91 papers in Molecular Biology, 68 papers in Oncology and 31 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in David F. Stern's work include HER2/EGFR in Cancer Research (43 papers), Monoclonal and Polyclonal Antibodies Research (30 papers) and DNA Repair Mechanisms (26 papers). David F. Stern is often cited by papers focused on HER2/EGFR in Cancer Research (43 papers), Monoclonal and Polyclonal Antibodies Research (30 papers) and DNA Repair Mechanisms (26 papers). David F. Stern collaborates with scholars based in United States, Switzerland and Canada. David F. Stern's co-authors include David J. Riese, Robert A. Weinberg, Xingzhi Xu, Mark I. Greene, Jeffrey A. Drebin, Anita B. Roberts, N S Roche, Michael B. Sporn, Bartholomew M. Sefton and David S. Fay and has published in prestigious journals such as Nature, Science and Cell.

In The Last Decade

David F. Stern

137 papers receiving 12.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Type beta transforming growth factor: a bifunctional regulator of cellular growth.

1985 972 citations David F. Stern et al. Proceedings of the National Academy of Sciences profile →
The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen

1984 938 citations David F. Stern et al. profile →
Specificity within the EGF family/ErbB receptor family signaling network

1998 671 citations David F. Stern et al. profile →

Peers

Countries citing papers authored by David F. Stern

Since Specialization

Citations

This map shows the geographic impact of David F. Stern's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David F. Stern with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David F. Stern more than expected).

Fields of papers citing papers by David F. Stern

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David F. Stern. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David F. Stern. The network helps show where David F. Stern may publish in the future.

Co-authorship network of co-authors of David F. Stern

This figure shows the co-authorship network connecting the top 25 collaborators of David F. Stern. A scholar is included among the top collaborators of David F. Stern based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David F. Stern. David F. Stern is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Acquired Resistance to HER2-Targeted Therapies Creates Vulnerability to ATP Synthase Inhibition 2019 ·Cancer Research ·Molly Gale, Yao Li, Jian Cao, Zongzhi Liu, Marissa A. Holmbeck, Meiling Zhang, Sabine M. Lang, Lizhen Wu, (unknown), Swati Gupta, Keisuke Aoshima, Michael P. DiGiovanna, David F. Stern, David L. Rimm, Gerald S. Shadel, Xiang Chen, Qin Yan	36
2	Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation Inhibitor 2017 ·Molecular Cancer Therapeutics ·Casey G. Langdon, James T. Platt, Robert E. Means, (unknown), Ramanaiah Mamillapalli, (unknown), Matthew A. Held, Jong Woo Lee, Ja Seok Koo, Christos Hatzis, Howard S. Höchster, David F. Stern	12
3	A Computational Approach for Identifying Synergistic Drug Combinations 2017 ·PLoS Computational Biology ·Kaitlyn Gayvert, Omar M. Aly, James T. Platt, Marcus Bosenberg, David F. Stern, Olivier Elemento	66
4	Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer 2016 ·Cancer Research ·Vikram B. Wali, Casey G. Langdon, Matthew A. Held, James T. Platt, Gauri A. Patwardhan, Anton Safonov, Bilge Aktaş, Lajos Pusztai, David F. Stern, Christos Hatzis	38
5	PMCA2 regulates HER2 protein kinase localization and signaling and promotes HER2-mediated breast cancer 2016 ·Proceedings of the National Academy of Sciences ·Jaekwang Jeong, Joshua VanHouten, Pamela Dann, Wonnam Kim, Catherine Sullivan, Herbert Yu, Lance A. Liotta, Virginia Espina, David F. Stern, Peter A. Friedman, John J. Wysolmerski	66
6	BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume 2015 ·Molecular Cancer Therapeutics ·Nicholas Theodosakis, Matthew A. Held, (unknown), Katrina Meeth, Goran Micevic, Georgina V. Long, Richard A. Scolyer, David F. Stern, Marcus Bosenberg	29
7	PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets 2015 ·Cancer Research ·Marzia Scortegagna, Eric Lau, Tongwu Zhang, Yongmei Feng, Chris Sereduk, Hongwei Yin, Surya K. De, Katrina Meeth, James T. Platt, Casey G. Langdon, Ruth Halaban, Maurizio Pellecchia, Michael A. Davies, Kevin M. Brown, David F. Stern, Marcus Bosenberg, Ze’ev A. Ronai	44
8	Convergent and Divergent Cellular Responses by ErbB4 Isoforms in Mammary Epithelial Cells 2014 ·Molecular Cancer Research ·Vikram B. Wali, Jonathan W. Haskins, Maureen Gilmore-Hebert, James T. Platt, Zongzhi Liu, David F. Stern	20
9	Enhancing Reproducibility in Cancer Drug Screening: How Do We Move Forward? 2014 ·Cancer Research ·Christos Hatzis, Philippe L. Bédard, Nicolai J. Birkbak, Andrew H. Beck, Hugo J.W.L. Aerts, David F. Stern, Leming Shi, Robert Clarke, John Quackenbush, Benjamin Haibe‐Kains	67
10	EGF Receptor Activates MET through MAPK to Enhance Non–Small Cell Lung Carcinoma Invasion and Brain Metastasis 2013 ·Cancer Research ·Jerrica L. Breindel, Jonathan W. Haskins, (unknown), Minghui Zhao, Don X. Nguyen, David F. Stern	98
11	Genotype-Selective Combination Therapies for Melanoma Identified by High-Throughput Drug Screening 2012 ·Cancer Discovery ·Matthew A. Held, Casey G. Langdon, James T. Platt, (unknown), Zongzhi Liu, Ashok K. Chakraborty, Antonella Bacchiocchi, Andrew B. Koo, Jonathan W. Haskins, Marcus Bosenberg, David F. Stern	96
12	Phosphoproteomic Screen Identifies Potential Therapeutic Targets in Melanoma 2011 ·Molecular Cancer Research ·(unknown), Garima Singhal, Sebastian Szpakowski, Christina Ivins Zito, Antonella Bacchiocchi, Viswanathan Muthusamy, Marcus Bosenberg, Michael Krauthammer, Ruth Halaban, David F. Stern	73
13	NFBD1/MDC1 Regulates Cav1 and Cav2 Independently of DNA Damage and p53 2011 ·Molecular Cancer Research ·(unknown), Sierra A. Colavito, Vincent Schulz, (unknown), William C. Sessa, David Tuck, David F. Stern	8
14	Relationship of Epidermal Growth Factor Receptor Expression to ErbB-2 Signaling Activity and Prognosis in Breast Cancer Patients 2005 ·Journal of Clinical Oncology ·Michael P. DiGiovanna, David F. Stern, Susan M. Edgerton, (unknown), Dan H. Moore, Ann D. Thor	193
15	Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases 2000 ·Breast Cancer Research ·David F. Stern	115
16	Expression of dominant-negative ErbB2 in the mammary gland of transgenic mice reveals a role in lobuloalveolar development and lactation 1999 ·Oncogene ·Frank E. Jones, David F. Stern	94
17	Type 1 receptor tyrosine kinases are differentially phosphorylated in mammary carcinoma and differentially associated with steroid receptors. 1996 ·PubMed ·Sarah Bacus, D Chin, Yosef Yarden, C R Zelnick, David F. Stern	77
18	An extra cysteine proximal to the transmembrane domain induces differential cross-linking of p185neu and p185neu. 1992 ·Journal of Biological Chemistry ·(unknown), (unknown), Claudia Dompé, Barbara J. Bormann, David F. Stern	26
19	A subdomain in the transmembrane domain is necessary for p185neu* activation. 1992 ·The EMBO Journal ·(unknown), (unknown), Barbara J. Bormann, David F. Stern	69
20	TPA inhibits the tyrosine kinase activity of the neu protein in vivo and in vitro. 1991 ·PubMed ·(unknown), (unknown), David F. Stern	19

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact